Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced registered direct offering of an aggregate of 800,877 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.285 per share of common stock (or common stock equivalent in lieu thereof), priced at-the-market under Nasdaq rules. The Company also issued to each investor, in a concurrent private placement, warrants to purchase up to an aggregate of 800,877 shares of common stock. The warrants have an exercise price of $2.16 per share, are immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance.
加利福尼亞州聖迭戈/ACCESSWIRE/2023年5月26日/德瑪塔治療公司(以下簡稱德瑪達)(納斯達克市場代碼:DRMA;DRMAW)是一家專注於治療醫學和美容皮膚病的臨床階段生物技術公司。該公司今天宣佈,其先前宣佈的登記直接發售普通股(或等值普通股)總計800,877股的交易結束,收購價為每股普通股(或等值普通股)2.285美元,根據納斯達克規則按市價定價。該公司還以同時私募的方式向每位投資者發行認股權證,購買總計800,877股普通股。這些認股權證的行使價為每股2.16美元,可在發行時立即行使,自發行之日起五年半到期。
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
H.C.Wainwright&Co.擔任此次發行的獨家配售代理。
The gross proceeds to the Company from the registered direct offering and the concurrent private placement were approximately $1.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to our technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.
在扣除配售代理費和本公司應付的其他發售費用前,本公司從登記直接發售和同時進行的私募所得款項總額約為180萬美元。該公司打算將淨收益用於一般企業目的,包括但不限於正在進行的研究和臨床前研究、臨床試驗、新的生物和製藥技術的開發、投資或收購與我們的技術協同或互補的公司、與我們當前和未來的候選產品相關的許可活動、以及新興技術的開發、投資或收購正在開發新興技術的公司、許可活動或收購其他業務和營運資本。
The securities described above (excluding the warrants and the shares of common stock underlying the warrants) were offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form S-3 (File No. 333-268383) that was originally filed with the Securities and Exchange Commission (the "SEC") on November 15, 2022, and declared effective on November 25, 2022. The offering of such securities in the registered direct offering was made only by means of a prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering were filed with the SEC and are available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus may also be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
上述證券(不包括認股權證及認股權證相關普通股股份)由本公司根據最初於2022年11月15日向美國證券交易委員會(“美國證券交易委員會”)提交並於2022年11月25日宣佈生效的S-3表格“擱置”登記聲明(第333-268383號檔案)以登記直接發售方式發售。在登記的直接發行中發行這類證券,只能通過構成有效登記說明書一部分的招股說明書補編進行。與已登記的直接發行相關的最終招股說明書附錄和隨附的基本招股說明書已提交給美國證券交易委員會,並可在美國證券交易委員會的網站www.sec.gov上查閱。最後的招股說明書附錄和隨附的基本招股說明書的電子版也可以從H.C.Wainwright&Co.,LLC那裡獲得,地址是:紐約公園大道430號,3樓,NY 10022,電話:(2128565711)或電子郵件:Placements@hcwco.com.
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
上述認股權證是根據修訂後的1933年《證券法》第4(A)(2)節及其頒佈的D法規以非公開方式發行的,與認股權證相關的普通股股份尚未根據該法或適用的州證券法進行登記。因此,認股權證和普通股的相關股份不得在美國發行或出售,除非有有效的註冊聲明或適用的豁免,不受該法案和相關州證券法的註冊要求的約束。
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
本新聞稿不構成出售或徵求購買本文所述任何證券的要約,也不得在任何州或其他司法管轄區出售這些證券,在這些州或其他司法管轄區,在根據任何此類州或其他司法管轄區的證券法進行註冊或獲得資格之前,此類要約、徵求或出售將是非法的。
About Dermata Therapeutics, Inc.
皮瑪塔治療公司簡介
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. The Company's lead product candidate, DMT310, is the Company's first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit
皮瑪塔治療公司是一家臨床階段的生物技術公司,專注於治療醫學和美容皮膚疾病和條件。該公司的主要候選產品DMT310是該公司從其海綿技術平臺。DMT310是一種每週一次的局部候選產品,來自天然來源的淡水海綿,具有多種獨特的作用機制。DMT310已被研究用於治療痤瘡、酒渣鼻和牛皮癬。該公司的第二個候選產品DMT410使用其海綿技術作為一種局部皮內注射肉毒桿菌毒素的新方法,用於治療多汗症和多種美容皮膚狀況。德瑪塔的總部設在加利福尼亞州的聖地亞哥。欲瞭解更多資訊,請訪問
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements pertaining to Dermata's expectations regarding the intended use of proceeds from the offering in this press release constitute forward-looking statements.
本新聞稿包含符合修訂後的1933年證券法第27A節和修訂後的1934年證券交易法第21E節的前瞻性陳述。本新聞稿中與德爾瑪塔預期的上市收益預期有關的所有陳述均為前瞻性陳述。
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, such as market and other conditions, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include market conditions, as well as those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
這些表述可以通過使用前瞻性表述來識別,包括但不限於“預期”、“預期”、“打算”、“計劃”、“相信”、“估計”、“潛在”、“預測”、“專案”、“應該”、“將”以及類似的表述和這些術語的否定。這些表述與未來事件或我們的財務表現有關,涉及已知和未知的風險、不確定性和其他因素,如市場和其他條件,這些因素可能導致實際結果、業績或成就與前瞻性表述中明示或暗示的任何未來結果、業績或成就大不相同。這些因素包括市場狀況、該公司截至2022年12月31日的10-K表格年度報告以及該公司此後不時提交給證券交易委員會的其他檔案中所述的那些因素。告誡潛在投資者不要過度依賴此類前瞻性陳述,這些陳述僅在本新聞稿發佈之日發表。除非法律要求,否則公司不承擔公開更新任何前瞻性陳述的義務,無論是由於新資訊、未來事件還是其他原因。
For more information, contact:
如需更多資訊,請聯繫:
Dermata Therapeutics, Inc.
皮瑪塔治療公司
Sean Proehl
Senior Director, Legal and Business Development
info@dermatarx.com
肖恩·普羅爾
董事高級法律和業務發展部
郵箱:Info@dermatarx.com
SOURCE: Dermata Therapeutics
資料來源:皮膚治療學